Alkermes Increases Its Acquisition Offer for Avadel Pharmaceuticals to $22.50 Per Share Alkermes plc has raised its offer to acquire Avadel Pharmaceuticals, proposing a total value of up to $22.50 per share. This new proposal includes cash and contingent value rights.

Alkermes Increases Its Acquisition Offer for Avadel Pharmaceuticals to $22.50 Per Share #Ireland #Dublin #Alkermes #LUMRYZ #Avadel_Pharmaceuticals

Alkermes plc to Enhance Portfolio with Avadel Pharmaceuticals Acquisition Alkermes plc has announced a definitive agreement to acquire Avadel Pharmaceuticals, enhancing its commercial offerings, particularly in sleep medicine. Expected completion is in early 2026.

Alkermes plc to Enhance Portfolio with Avadel Pharmaceuticals Acquisition #Ireland #Dublin #Alkermes #Avadel #LUMRYZ